AlphAIAlphAI — Financial news for AI agents
tipranks.comOCT 151 min read$MRNA

Moderna price target raised to $137 from $120 at Goldman Sachs

Goldman Sachs raised its price target for Moderna (MRNA) to $137 from $120, maintaining a Neutral rating. The firm cited upcoming Phase 3 results for melanoma and Phase 1 data for pancreatic cancer as key catalysts. TipRanks identified three Vanguard ETFs (VO, VNQ, VBR) with potential upside, based on analyst consensus and price targets.

Original reporting
tipranks.com
Published Oct 15, 2026, 10:15 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 15, 2026, 12:30 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefFinancial news
Primary signal
$MRNA
Bullish
high confidence
Mentioned
$MRNA
Relevance
7/10
AlphAI data visualization · based on tipranks.com
Decision brief

The 30-second read

$MRNABullishMed
01

Why it matters

The price target lift reflects optimism about these upcoming data releases, but actual market reaction will depend on trial outcomes.

02

Market read

Analyst target raise may prompt short-term buying, especially ahead of pivotal trial data.

03

What to watch

Potential regulatory delays or competition could offset the upside.

Relevance 7/10Novelty 7/10Timing: immediate

Background

Moderna is awaiting Phase 3 melanoma results at ESMO and Phase 1 pancreatic data, which are key catalysts for the stock.

Company-level read

Ticker impact

$MRNABullishHigh confidence
Context

Goldman Sachs raised Moderna's price target to $137 from $120 and kept a Neutral rating.

Expected impact

potential upside as investors price in higher target

Evidence & confidence

Target increase signals improved expectations for upcoming trial data, prompting buying interest.

Market effects

Sector

Biotech sector may see modest uplift as a major analyst raises a key player.

Regional

U.S. biotech stocks could experience slight positive pressure.

Global

Limited to investors tracking biotech pipelines and analyst coverage.

Counterpoint

What could challenge this read

Target raise may be premature if upcoming trial data disappoints.

Key entities

  • Analyst
    Goldman Sachs

    Provided the upgraded price target and neutral rating.

  • Company
    Moderna Inc.

    Biotech firm developing mRNA therapies.

Read at source← All news

StoryGoldman Sachs raises Moderna price target while keeping Neutral rating

Related articles

OCT 15
$MRNAMed

Moderna (MRNA) Shares Surge on Cancer Vaccine Data Ahead of Late

Moderna (MRNA) shares rose 38% since late September ahead of a presentation on late-stage trial data for its cancer vaccine, developed with Merck (MRK). The rally follows a 170% surge after positive Phase 3 melanoma trial results in August. Moderna's P/S ratio is 41.76, significantly higher than its historical median of 8.48, reflecting market growth expectations despite its unprofitability. Insider activity shows no purchases and $64.6M in sales over the past year.

gurufocus.com6 min
OCT 15
$MRNAHigh

Moderna Stock Is Soaring on Cancer Vaccine Buzz. Is It Too Late to Get In?

Moderna's stock rose 658.2% year-to-date, reaching $223.60 premarket. The surge followed positive late-stage trial results for its cancer vaccine, developed with Merck. Analysts' price targets are below current levels, with a consensus at $122.67. Moderna reports Q3 earnings on November 6, with revenue and cash flow expectations to be revealed. The stock trades at 38.75 times trailing sales, raising valuation concerns.

247wallst.com2 min
OCT 15
$MRNAMed

MRNA Maintains Neutral Rating -- Price Target Raised to $137

Goldman Sachs maintained a Neutral rating on Moderna (MRNA) but raised its price target to $137 from $120. GuruFocus values MRNA at $23.84, suggesting it is 849.2% overvalued. The company has a GF Score of 54/100, with strengths in financial stability but weaknesses in profitability and valuation. Insider selling totaled $49.18M over the past three months.

gurufocus.com2 min
OCT 14
$MRNAHigh

MRNA Stock Surges On Cancer Vaccine Catalysts And Nasdaq-100 Move

Moderna Inc. (MRNA) shares rose 4.13% on October 14, 2026, driven by optimism around its mRNA cancer vaccine pipeline and inclusion in the Nasdaq-100 Index. The company reported $143M in revenue and a net loss of $782M for the latest quarter, with $5.1B in cash reserves. Analysts have adjusted price targets, with Bank of America raising its target to $200 and Morgan Stanley to $95, both maintaining cautious ratings. The next key catalyst is Moderna's Q3 2026 earnings report on November 6, 2026.

timothysykes.com3 min
OCT 14
$MRNAMed

MRNA Stock Surges As Cancer Vaccine Hopes And Nasdaq-100 Nod Align

Moderna Inc. (MRNA) stock rose 4.22% on October 14, 2026, driven by positive mRNA pipeline data and inclusion in the Nasdaq-100 index. The company reported Q2 2026 revenue of $143M, a net loss of $782M, and has $5.14B in cash. The US NIH's cancer vaccine initiative and Moderna's oncology ambitions are key catalysts. Analysts have mixed price targets, with Bank of America at $200 and Morgan Stanley at $95.

stockstotrade.com4 min
OCT 14
$MRNAHighAI 9/10

Personalised cancer vaccines take a leap forward – can Swiss pharma catch up?

Moderna and MSD announced successful Phase III trial results for a personalized mRNA cancer vaccine, showing reduced melanoma recurrence. Roche and BioNTech halted a Phase II trial for colorectal cancer. Moderna's shares surged 60%, MSD's rose 6%. Analysts discuss implications for Swiss pharma giants Roche and Novartis, focusing on trial differences and market potential. Challenges include manufacturing time and cost.

swissinfo.ch3 min